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The aberrant aggregation of proteins is a key molecular event in the development and
progression of a wide range of neurodegenerative disorders. We have shown previously
that squalamine and trodusquemine, two natural products in the aminosterol class, can
modulate the aggregation of the amyloid-β peptide (Aβ) and of α-synuclein (αS), which
are associated with Alzheimer’s and Parkinson’s diseases. In this work, we expand our
previous analyses to two squalamine derivatives, des-squalamine and α-squalamine,
obtaining further insights into the mechanism by which aminosterols modulate Aβ and
αS aggregation. We then characterize the ability of these small molecules to alter the
physicochemical properties of stabilized oligomeric species in vitro and to suppress the
toxicity of these aggregates to varying degrees toward human neuroblastoma cells. We
found that, despite the fact that these aminosterols exert opposing effects on Aβ and αS
aggregation under the conditions that we tested, the modifications that they induced to
the toxicity of oligomers were similar. Our results indicate that the suppression of toxicity
is mediated by the displacement of toxic oligomeric species from cellular membranes
by the aminosterols. This study, thus, provides evidence that aminosterols could be
rationally optimized in drug discovery programs to target oligomer toxicity in Alzheimer’s
and Parkinson’s diseases.
Keywords: protein misfolding diseases, amyloid-β, Alzheimer’s disease, α-synuclein, Parkinson’s disease,
oligomers, aminosterols, small molecule drug discovery
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INTRODUCTION
Numerous neurodegenerative diseases are characterized by a
complex pathophysiology that has made highly challenging the
identification of targets for drug discovery and the development
of clinical treatments (Cummings et al., 2014; Knowles et al.,
2014; Chiti and Dobson, 2017). The aberrant misfolding,
aggregation, and deposition of amyloid-β peptide (Aβ) and
α-synuclein (αS) into pathological aggregates plays a central
role in Alzheimer’s disease (AD) and Parkinson’s disease
(PD), and recent evidence has demonstrated that oligomeric
intermediates in the process of fibril formation are especially
deleterious toward neuronal cells (Kreiser et al., 2020). These
aggregates may, therefore, play a causative role in the onset
and propagation of protein misfolding diseases throughout the
central nervous system.
Much effort has been devoted toward understanding the
ability of a variety of molecules to modify the aggregation
reactions of these proteins (Dobson, 2003; Arosio et al., 2014;
Knowles et al., 2014; Chiti and Dobson, 2017), resulting in the
identification of species that enhance (Ladiwala et al., 2011;
Lam et al., 2016; Limbocker et al., 2019) or reduce fibril
formation (Ladiwala et al., 2011; Cohen et al., 2015; Habchi
et al., 2016, 2017; Perni et al., 2017, 2018; Eskandari et al.,
2020). Recent advances using chemical kinetics have enabled
the characterization of numerous species that target specifically
the microscopic steps governing protein aggregation, including
primary nucleation, secondary nucleation, and elongation for
Aβ (Cohen et al., 2015; Habchi et al., 2016, 2017) and lipid-
induced nucleation, fibril amplification, and elongation for αS
(Buell et al., 2014; Galvagnion et al., 2015; Flagmeier et al., 2016;
Perni et al., 2018). Coupled with an analysis of the effects of
the molecules on intermediate species in vitro, toward cells and
after their administration to Caenorhabditis elegans expressing
human αS or Aβ in their muscle cells, one can understand in
detail the pathological consequences caused by perturbing the
aggregation reaction with molecular species (Perni et al., 2017,
2018; Limbocker et al., 2019).
In addition to modulating the rates of oligomer formation,
key studies have been carried out to identify the biophysical
properties responsible for the oligomer-induced damage to
cell membranes (Campioni et al., 2010; Bemporad and Chiti,
2012; Mannini et al., 2014; Cappelli et al., 2016; Chiti and
Dobson, 2017; Fusco et al., 2017; Limbocker et al., 2020a).
The relationship between oligomer size and hydrophobicity
and their ability to embed and damage cell membranes
provides insight into the origins of oligomer toxicity and
illuminates a potential therapeutic avenue toward counteracting
such toxicity. Specifically, it has been demonstrated that size
and hydrophobicity are oppositely correlated to the ability
of oligomers to damage cells, where small and hydrophobic
oligomers are more toxic than larger and less hydrophobic ones
(Mannini et al., 2014).
Aminosterols consist of a fused sterol linked to a polyamine
side chain and are natural products originally discovered in
the dogfish shark (Rao et al., 2000). As a class of naturally
occurring molecules, aminosterols have been investigated for
a host of medical applications ranging from obesity (Ahima
et al., 2002), tissue regeneration (Smith et al., 2017), and
cancer (Krishnan et al., 2014), to effective modulators of protein
aggregation (Perni et al., 2017, 2018; Limbocker et al., 2019).
Squalamine was first characterized for its ability to inhibit lipid-
induced nucleation and to protect cell membranes by displacing
oligomeric aggregates of αS at relatively low concentrations
(Perni et al., 2017). Later on, we found that trodusquemine
enhances the rate of aggregation of the 42-residue form of Aβ
(Aβ42) by potentiating predominantly the secondary nucleation
microscopic step (Limbocker et al., 2019) and inhibits αS
aggregation by suppressing both the lipid-induced nucleation
and fibril amplification processes (Perni et al., 2018). In both
cases, this molecule could reduce the lifetime or number of
oligomeric species by catalyzing their conversion to the fibrillar
form for Aβ42 (Limbocker et al., 2019) or attenuating their
rate of formation for αS (Perni et al., 2018). Trodusquemine
prevents the toxicity of isolated or stabilized oligomers comprised
of the 40-residue form of Aβ (Aβ40), Aβ42, αS, and the model
protein HypF-N by binding to the cell membrane (Errico et al.,
2020), outcompeting oligomers at the cell membrane, and therein
displacing these aggregates from cell membranes through a
conserved mechanism (Perni et al., 2018; Limbocker et al., 2019,
2020b). Trodusquemine was found not to directly target either
the size or hydrophobicity of the oligomers at physiological
concentrations, but instead to function through a mechanism
based on oligomer displacement from the cell membrane in
addition to its ability to modulate the kinetics of their assembly
(Perni et al., 2018; Limbocker et al., 2019, 2020b). Finally,
squalamine was recently reported to prevent the aggregation of
αS and its associated toxicity in new C. elegans models of familial
forms of PD, where its beneficial effect was more pronounced in
A53T worms than in the A30P ones (Perni et al., 2021).
In this report, we sought to resolve the effects of different
aminosterols, including trodusquemine (TRO), squalamine (SQ),
α-squalamine (αSQ), and des-squalamine (desSQ), on the
aggregation reactions of Aβ and αS. By investigating the kinetics
of oligomer formation, the structural properties of oligomers
upon aminosterol addition at both physiological and molar
excess concentrations, and using tissue culture experiments,
we demonstrate that subtle structural differences in these
aminosterols can lead to differential efficacies in preventing the
toxicity linked to protein aggregation. In addition to providing
a framework to characterize relevant molecules, these results
further signal the relevance of aminosterols in the treatment of
protein misfolding diseases and suggest that future studies to
optimize aminosterol potency and efficacy may be possible.
MATERIALS AND METHODS
Reagents
Squalamine and its derivatives were synthesized as a dilactate,
and TRO as a hydrochloride salt at purity greater than 97% and
stored as a lyophilized powder. Aliquots were prepared at 10 mM
in water and stored at−20◦C.
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Preparation of Aβ42 for Chemical
Kinetics Experiments
The recombinant Aβ(M1–42) peptide (MDAEFRHDSGY
EVHHQKLVFF AEDVGSNKGA IIGLMVGGVV IA), denoted
Aβ42, was expressed in the Escherichia coli BL21 Gold (DE3)
strain (Stratagene, San Diego, CA, United States) and purified
as described previously (Habchi et al., 2017). The recombinant
Aβ(M1–40) peptide (MDAEFRHDSGY EVHHQKLVFF
AEDVGSNKGA IIGLMVGGVV), denoted Aβ40, was similarly
prepared. Samples were prepared for kinetic experiments
using standard reagents and methods. Briefly, monomeric
protein was purified in 20 mM sodium phosphate buffer
at pH 8 supplemented with 200 µM EDTA (Habchi et al.,
2017). Thioflavin-T (ThT, Sigma-Aldrich, St. Louis, MO,
United States) was added from a 1 mM stock to a final
concentration of 20 µM. All samples were prepared in
low-binding Eppendorf tubes, and samples were analyzed
in a 96-well half area, low-binding, clear-bottom PEG-
coated plate (Corning 3881, Sigma-Aldrich, St. Louis, MO,
United States). Fibril seeds were prepared as described previously
(Habchi et al., 2017).
Concentrations of ThT of 20 µM or below have been described
to exert minimal effects on aggregation kinetics experiments
(Xue et al., 2017). The effects of aminosterols have been
previously characterized not to be related to aminosterols binding
artifactually to ThT rather than amyloid aggregates (Perni et al.,
2018). Previous work used ThT to monitor the aggregation
kinetics of Aβ42 in the absence and presence of the primary
nucleation inhibitor bexarotene. The degree of inhibition, as
quantified with the ThT experiments, corresponded directly
to AFM and dot-blot measurements taken in the absence of
ThT both in the absence and presence of a fourfold excess
of bexarotene (Habchi et al., 2016), indicating that ThT does
not appear to alter the aggregation reaction both with and
without bexarotene under these conditions. While we cannot
completely exclude that ThT has some effect on the mechanisms
of the Aβ42 and αS aggregation reactions, it is unlikely that
the described effects of the aminosterols are related to ThT-
based artifacts.
Aβ42 Kinetic Analysis
ThT fluorescence was monitored in triplicate per sample as
measured using the bottom optic in a plate reader (Fluostar
Omega or Fluostar Optima from BMGLabtech, Aylesbury,
United Kingdom) with 440- and 480-nm excitation and
emission filters, respectively. Aggregation was initiated by
transferring the 96-well plate to the plate reader at 37◦C under
quiescent conditions. The time evolution of the total fibril mass
concentration, M(t) (Cohen et al., 2012, 2013), was analyzed as
described in the main text.
αS Expression and Lipid Preparation
Wild-type human αS was recombinantly expressed and purified
as described previously (Hoyer et al., 2002; Galvagnion et al.,
2016). For concentration measurements, an extinction coefficient
of 5,600 M−1 cm−1 was used at 275 nm. After the final
size exclusion chromatography (phosphate buffer, pH 6.5,
20 mM), the protein was snap frozen in liquid nitrogen in the
form of 1-ml aliquots and stored at −80◦C. The lipids were
dissolved in 20 mM phosphate buffer (NaH2PO4/Na2HPO4),
pH 6.5, 0.01% NaN3, and stirred at ca. 45◦C for 2 h. The
solution was then frozen and thawed five times using dry ice
and a water bath at 45◦C. The preparation of vesicles was
carried out using sonication at 3 × 5 min, 50% cycles, 10%
maximum power on ice with a Bandelin Sonopuls HD 2070
(Bandelin, Berlin, Germany). After centrifugation, the sizes of the
vesicles were checked using dynamic light scattering (Zetasizer
Nano ZSP, Malvern Instruments, Malvern, United Kingdom)
and were shown to consist of a distribution centered at a
diameter of 20 nm.
Aggregation Kinetics of αS in the
Presence of Lipid Vesicles
1,2-Dimyristoyl-sn-glycero-3-phospho-L-serine (sodium salt;
DMPS) was purchased from Avanti Polar Lipids (Alabaster,
AL, United States). αS was incubated at a concentration of
100 µM in 20 mM sodium phosphate, pH 6.5, 0.01% NaN3,
in the presence of 50 µM ThT, 100 µM DMPS vesicles, and
increasing concentrations of aminosterols (0–10 µM). The stock
solution of each aminosterol was prepared by dissolving the
molecule in 20 mM phosphate buffer to a final concentration of
100 µM. The change in the ThT fluorescence signal with time
was monitored using a Fluostar Optima or a Polarstar Omega
(BMG Labtech, Aylesbury, United Kingdom) under quiescent
conditions at 30◦C (Perni et al., 2017) in the above-described
Corning 3881 96-well plates.
Atomic Force Microscopy of Fibrils
Aβ42 fibrils were prepared by incubating the protein from its
monomeric state (2 µM) for 4 h in the absence or presence
of an equimolar concentration of SQ (2 µM) in the absence
of ThT. The incubation time of 4 h was selected as this
time is sufficient for all samples to enter the plateau phase
from ThT kinetics experiments. Mica substrates were positively
functionalized by their incubation with a 10-µl drop of 0.05%
(v/v) (3-aminopropyl)triethoxysilane (APTES, Sigma-Aldrich, St.
Louis, MO, United States) in Milli-Q water for 1 min at ambient
temperature, followed by rinsing with Milli-Q water and gentle
drying with gaseous nitrogen (Ruggeri et al., 2015, 2016). AFM
sample deposition was carried out at room temperature by
depositing a 10-µl drop of protein at a concentration of 2 µM for
2 min. to a mica surface treated with APTES. Salt was washed with
high-purity water, and samples were stored in a sealed container
until imaging using a JPK Nanowizard2 system (JPK Instruments,
Berlin, Germany) using tapping mode with scan rates <0.5 Hz
and a silicon tip with a 10-nm nominal radius (MikroMasch,
Wetzlar, Germany).
Transmission Emission Microscopy
Samples for TEM were prepared on a 400-mesh, 3-mm copper
grid carbon support film (EM Resolutions Ltd., Sheffield,
United Kingdom) and stained with 2% uranyl acetate (wt/vol)
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(Limbocker et al., 2019). The samples were imaged on a
FEI Tecnai G2 transmission electron microscope (Cambridge
Advanced Imaging Centre, CAIC, University of Cambridge,
United Kingdom). Images were acquired using the SIS Megaview
II Image Capture system (Olympus, Muenster, Germany).
αS Oligomer Preparation
αS was prepared as previously described (Chen et al., 2015).
Briefly, protein was purified into PBS, and subsequently dialyzed
against water (4 L, overnight at 4◦C). Six-milligram aliquots
were lyophilized for 2 days, followed by resuspension in
buffer (500 µl of 20 mM Tris, 100 mM NaCl, pH 7.4). The
resuspended protein was passed through 0.22-µm filters and
incubated (20–24 h, 37◦C). The samples were ultracentrifuged
(1 h, 90,000 rpm, 20◦C) in a TLA120.2 rotor, using an
Optima TLX Ultracentrifuge (both Beckman Coulter, High
Wycombe, United Kingdom) to remove aggregates and large
oligomers. The remaining monomer was removed using a
100-kDa centrifugation filter (4×) (2 min, 10,000 rpm). The
flow through containing predominantly monomer from the
first three passes was kept and reused up to five times.
Oligomer concentration was determined by UV spectroscopy,
using an extinction coefficient of 5,600 M−1cm−1 at a
wavelength of 275 nm.
Aβ40 Oligomer Preparation
All samples were prepared using LoBind tubes. Lyophilized
Aβ40 (0.5 or 1.0 mg) was solubilized to a monomeric
form overnight in 300 µl of HFIP. The following day, the
solvent was gently evaporated off with nitrogen, and the
protein resuspended in 100% DMSO with thorough pipetting
at a final concentration of 2.2 mM. Two sonication steps
of 10 min were preformed, then protein was resuspended
at 100 µM in 20 mM sodium phosphate buffer, 200 µM
ZnCl2, pH 6.9 (Mannini et al., 2018). After 20 h at 20◦C,
samples were spun down at 15,000 rpm at 20◦C for 15 min.
The supernatant was removed, and the pellet containing the
oligomers was resuspended in buffer (20 mM Tris, 100 mM
NaCl at pH 7.4). While Aβ42 is generally more toxic than
Aβ40, it is challenging to carry out a comprehensive biophysical
characterization of Aβ42 oligomers as they are difficult to prepare
in a stable, homogeneous population in near-physiological
conditions (Kulenkampff et al., 2021). As such, we elected to
investigate oligomers of Aβ40 stabilized by zinc ions (Zn2+),
which can be generated at near-physiological conditions in a
stable, homogenous population. Moreover, Aβ40 comprises a
majority of the insoluble amyloidogenic plaques in the AD
brain and is, therefore, an important oligomeric agent in disease
(Mannini et al., 2018).
HypF-N Oligomer Preparation
HypF-N was purified as previously reported (Campioni et al.,
2010; Capitini et al., 2018). Type A toxic oligomers were prepared
as previously described (Campioni et al., 2010). Briefly, purified
wild-type monomeric HypF-N was resuspended at 0.5 mg/ml in
12% TFE, 2 mM DTT, 50 mM acetate buffer, pH 5.5 to a total
volume of 500 µl and incubated in a water bath at 25◦C. After
4 h of incubation, protein was spun down at 16,100 × g at 20◦C
for 15 min. The supernatant was removed, and residual solvent
was evaporated off by gently drying the pellet with nitrogen gas,
and the pellet containing the oligomers was resuspended in buffer
(20 mM Tris, 100 mM NaCl at pH 7.4).
Preparation of Aβ-Derived Diffusible
Ligand Oligomers of Aβ42
Lyophilized Aβ42 (Sigma-Aldrich, St. Louis, MO, United States)
was dissolved in 100% hexafluoro-2-isopropanol (HFIP) to
1.0 mM, and then the solvent was evaporated. Aβ-derived
diffusible ligands of Aβ42 (ADDLs) oligomers were then prepared
according to the Lambert’s protocol (Lambert et al., 2001).
Aminosterol Incubation With Oligomers
After oligomer formation, samples were incubated in the absence
or presence of aminosterols for 1 h at 20◦C in 20 mM Tris,
100 mM NaCl at pH 7.4. Samples were prepared at a final
concentration of 5 µM oligomers, and aminosterols were added
at 1-, 2. 5-, 5-, 7. 5-, and 10-fold excesses, unless otherwise stated.
8-Anilinonaphthalene-1-Sulfonate
Binding Measurements
Solutions with oligomers at a concentration of 5 µM in buffer
(20 mM Tris, 100 mM NaCl at pH 7.4) were aliquoted, and
8-anilinonaphthalene-1-sulfonate (ANS) was added to a final
concentration of 15 µM from a concentrated stock. Emission
spectra were recorded using a plate reader (BMG Labtech,
Aylesbury, United Kingdom) with excitation at 380 nm. Spectra
were background subtracted to that of the spectra of buffer alone.
Turbidity Measurements
Samples from the ANS preparation were analyzed using a plate
reader (BMG Labtech, Aylesbury, United Kingdom) with spectral
scanning. Spectra were background subtracted to that of the
spectra of buffer alone.
Atomic Force Microscopy of Oligomers
Oligomers were incubated at 5 µM in 20 mM Tris, 100 mM
NaCl at pH 7.4 in the absence or presence of 25 µM SQ.
All samples were diluted by a factor of five and subsequently
sprayed at 100 µl/h for 1 min at room temperature using a
recently described microfluidic device (Ruggeri et al., 2018)
atop an atomically flat MICA surface. AFM measurements
were performed by using a Park NX10 AFM (Park Systems,
Suwon, South Korea) with scan rates <0.3 Hz and PPP-
NCHR cantilevers with an 8-nm nominal radius (Nanosensors,
Neuchatel, Switzerland).
Neuroblastoma Cell Culture
Human SH-SY5Y neuroblastoma cells (ATCC, Manassas, VA,
United States) were cultured in DMEM, F-12 HAM with 25 mM
HEPES, and NaHCO3 (1:1) and supplemented with 10% FBS,
1 mM glutamine, and 1.0% antibiotics. Cell cultures were
maintained in a 5% CO2 humidified atmosphere at 37◦C and
grown until they reached 80% confluence for a maximum of 20
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passages (Cascella et al., 2019). The cell line was authenticated
and tested negative for mycoplasma contamination.
MTT Reduction Assay
Zn2+-stabilized Aβ40 (Mannini et al., 2018) (5 µM, in monomer
equivalents), HypF-N (Campioni et al., 2010) (6 µM, in
monomer equivalents), and ADDLs of Aβ42 oligomers
(Lambert et al., 2001) (1 µM, in monomer equivalents) were
incubated with or without increasing concentrations of SQ for
1 h at 37◦C under shaking conditions, and then added to the cell
culture medium of SH-SY5Y cells seeded in 96-well plates for
24 h. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) reduction assay was performed as previously
described (Cascella et al., 2017).
Oligomer Binding to the Cellular
Membrane
SH-SY5Y cells were seeded on glass coverslips and treated
for 15 min with oligomers of various proteins at the listed
concentrations in the absence or presence of SQ. After
incubation, the cells were washed with PBS and counterstained
with 5.0 µg/ml of Alexa Fluor 633-conjugated wheat germ
agglutinin (Life Technologies, CA, United States) (Perni et al.,
2017). After washing with PBS, the presence of oligomers
was detected with 1:800 diluted mouse monoclonal 6E10
anti-Aβ antibodies (BioLegend, San Diego, CA, United States)
or 1:800 rabbit anti-HypF-N antibodies (Primm, Milan,
Italy) and subsequently with 1:1,000 diluted Alexa Fluor
488-conjugated anti-mouse or anti-rabbit secondary antibodies
(Life Technologies, CA, United States). Fluorescence emission
was detected after double excitation at 488 and 633 nm by
a scanning confocal microscopy system (Perni et al., 2017),
and three apical sections were projected as a single composite
image by superimposition. ImageJ (NIH, Bethesda, MD,
United States) and JACOP plugin (rsb.info.nih.gov) software
were used to calculate the percentage of colocalization between
cell membranes and oligomers.
Statistics
Data were analyzed using GraphPad Prism 8 (CA, United States)
using an unpaired, two-tailed Student’s t-test or one-way ANOVA
followed by Bonferroni’s post comparison test relative to cells
treated with culture media or oligomers, as indicated in the
corresponding figure legends.
RESULTS
In this work, we analyzed four aminosterols, squalamine
(SQ), des-squalamine (desSQ), α-squalamine (αSQ), and
trodusquemine (TRO), with slightly different physicochemical
properties (Figure 1). The investigation of the addition of
polyamine groups to a sterol moiety is particularly interesting
following recent reports about the remarkable ability of
polyamines to modulate cellular homeostasis (Schroeder et al.,
2021; Liang et al., 2021). TRO contains a spermine moiety as
its polyamine side chain, while SQ and its derivatives have
FIGURE 1 | Structures of the four aminosterols investigated in this work. Squalamine (SQ, red), des-squalamine (desSQ, green), α-squalamine (αSQ, orange), and
trodusquemine (TRO, blue) with unique molecular features indicated.
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a spermidine linked to the fused sterol ring. Within the SQ
derivatives, αSQ has inverted stereochemistry about the carbon
atom which links the spermidine to the sterol, while desSQ lacks
the SO4H group on its alkyl chain (Figure 1). At neutral pH,
TRO has a net charge of +3. SQ and αSQ bear one less positive
charge relative to TRO on its side chain, and SQ was initially
discovered in the dogfish shark liver at a ratio of SQ to TRO of
99:1 (Rao et al., 2000). DesSQ has the same net positive charge
relative to TRO. We sought to determine if either inverting the
stereochemistry or removing the SO3H group to increase its
overall charge by one, as occurring in αSQ and desSQ relative
to SQ, respectively, would impact the efficacy of aminosterols in
modulating the rate of αS and Aβ protein aggregation or their
oligomer binding to cell membranes.
Effects of the Aminosterols on the
Aggregation Kinetics of Aβ42 and αS
The kinetics underpinning protein aggregation play a key role in
the production of oligomeric species, which are highly toxic to
cells (Chia et al., 2018; Michaels et al., 2020). A great deal of work
has been carried out to determine the effect of additive agents
to the aggregation of the Aβ peptide, including small molecules
(Habchi et al., 2016, 2017, 2018; Chia et al., 2018; Limbocker et al.,
2019), molecular chaperones (Cohen et al., 2015), and antibodies
(Aprile et al., 2017; Limbocker et al., 2020a). Recent work has
shown that one can directly link the number of oligomers
produced during an aggregation reaction to the kinetics of their
fibrilization, where inhibitors decrease the number of oligomers
formed (Chia et al., 2018; Michaels et al., 2020).
We began this study by probing the effects of the
aminosterol derivatives on the aggregation of Aβ42. Past work
has demonstrated that TRO enhances the rate of secondary
nucleation in Aβ42 aggregation (Limbocker et al., 2019)
and reduces the rates of lipid-induced nucleation and fibril
amplification in αS aggregation (Perni et al., 2018). We first
carried out unseeded aggregation assays in vitro in the presence
of thioflavin-T (ThT) as described previously for Aβ42 (Habchi
et al., 2017) to evaluate the effects of aminosterols on the
aggregation processes of this protein. The aggregation of
FIGURE 2 | Aminosterols accelerate Aβ42 aggregation in vitro. Kinetic profiles of the aggregation of 2 µM Aβ42 in the absence (black) or presence of 0.2 µM (green),
0.4 µM (orange), and 2 µM (red) of TRO (A), SQ (B), αSQ (C), and desSQ (D). Data represent mean ± standard error of the mean (s.e.m.) of three technical
replicates. Raw ThT aggregation data are provided in Supplementary Figure 1. (E) AFM images at t = 0 h (top panels, scale bars = 0.2 µm) and t = 4 h (bottom
panels, scale bars = 1 µm) of aggregation in the absence (left panels) and presence of an equimolar concentration of SQ (right panels). (F) TEM images of fibrils
formed after 4 h of aggregation in the absence (top) or presence of an equimolar concentration of SQ (bottom). Scale bars = 100 nm. AFM and TEM measurements
were taken alongside a comparison of the effect of TRO on Aβ42 aggregation, and the untreated fibrils, therefore, have the same population statistics as previously
published (Limbocker et al., 2019).
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2 µM Aβ42 was monitored in the absence and presence of
increasing concentrations of each aminosterol (0.2, 0.4, and
2 µM) (Figures 2A–D and Supplementary Figure 1). As the
aggregation reaction for Aβ42 plateaus upon monomer depletion,
we normalized each condition to the plateau phase of the ThT
trace to obtain the normalized fibril mass concentration over
time in Figures 2A–D, while the raw ThT data can be found in
Supplementary Figure 1. In the presence of all these compounds,
Aβ42 aggregation was enhanced.
We next sought to assess the effects of the aminosterols on
further processes governing Aβ42 aggregation, namely, secondary
nucleation and elongation (Habchi et al., 2017; Limbocker
et al., 2019). In light of the similarity in behavior between the
aminosterols in the unseeded aggregation assays, we elected to
quantify only the effects of SQ to facilitate a comparison with
TRO that was published previously (Limbocker et al., 2019).
Seeded aggregation assays with Aβ42 at a concentration of 2 µM
were carried out in the presence of a low concentration of fibril
seeds (i.e., 5% fibrils, in monomer equivalents), where primary
nucleation is not rate limiting, and with a high concentration
of fibril seeds (i.e., 25% fibrils, in monomer equivalents), where
elongation is the rate-determining step, in order to monitor the
effects of SQ on the microscopic rate constants associated with
the aggregation of Aβ42 (Habchi et al., 2017).
The aggregation of 2 µM Aβ42 was carried out in the
unseeded aggregation assay (Supplementary Figure 2a) and
in the presence of 5% preformed seed fibrils (Supplementary
Figure 2b), which caused a characteristic reduction in the
half-time of aggregation. Moreover, upon the addition of
increasing concentrations of SQ (0.2, 0.4, and 2 µM), the half-
times were further reduced (Supplementary Figure 2b). As
in this environment primary nucleation is not rate limiting,
the observed increase in aggregation is likely to be associated
with secondary nucleation pathways. We then followed the
aggregation of 2 µM Aβ42 in the presence of 25% preformed
seeds, which caused a dramatic reduction in the half-time of
aggregation. Again, the presence of increasing concentrations
of SQ (0.2, 0.4, and 2 µM) further reduced the half-time of
aggregation (Supplementary Figure 2c), but this enhancement
of aggregation was small in comparison with the unseeded and
5% seeded assays.
The time evolution of the total fibril mass concentration,
M(t), was described by an integrated rate law containing
combinations of the microscopic rate constants k+k2 and knk2,
where kn, k+, and k2 indicate primary nucleation, elongation,
and secondary nucleation rate constants, respectively (Cohen
et al., 2012, 2013). The perturbation induced by SQ was then
resolved by fitting experimental data to a master equation
to identify the alterations to the microscopic processes, as
described in detail previously (Habchi et al., 2017). Our results
reveal that the unseeded and 5% seeded data are well-described
by varying the rates associated with secondary nucleation
pathways, k+k2, or secondary nucleation, k2, respectively
(Supplementary Figures 2a,b, solid lines). Furthermore, fitting
the unseeded and 5% seeded data for an effect on k2 matched
the experimental data well (Supplementary Figure 2d, solid
lines), while fitting for primary nucleation events, kn, was less
accurate (Supplementary Figure 2e, solid lines). Moreover,
the seeded data suggest a weak increase in elongation and a
strong increase in secondary nucleation. Indeed, the 5% seeded
data are aptly described by varying only the rate associated
with secondary nucleation (Supplementary Figure 2b, solid
lines), and the rate of elongation alone is insufficient to
recapitulate the overall observed increase in aggregation in
all three of these assays. These results are comparable with
those previously described for TRO (Limbocker et al., 2019)
and suggest that these four aminosterols exert comparable
accelerating effects on secondary processes governing the Aβ42
aggregation reaction.
To validate the kinetic model and visualize the morphology
of the aggregates formed in the presence of aminosterols, we
carried out high-resolution and phase-controlled non-contact
atomic force microscopy (AFM). Fibrils were quantified after
incubation for 4 h in the absence and presence of an equimolar
concentration of SQ and in the absence of ThT by measuring
both their lengths and cross-sectional heights, where the latter
feature corresponds to the diameter of the aggregates (Figure 2E).
We found that fibril height was increased significantly in the
presence of SQ, from 4.2 ± 0.2 nm [mean ± total error, as
calculated in Limbocker et al. (2019); n = 387] in its absence
to 5.8 ± 0.4 nm (n = 138) in its presence (p < 0.001 by a
paired t-test). Additionally, the average fibril length was observed
to decrease in the presence of SQ, from 1.81 ± 0.12 µm
(n = 100) in its absence to 0.60 ± 0.06 µm (n = 100) in its
presence (p< 0.001 by a paired t-test), and transmission emission
microscopy images confirmed the reduction in fibril length by SQ
(Figure 2F). The fibril morphology is, therefore, in agreement
with the expectation that an increase in secondary nucleation
would shift the aggregation reaction toward the formation
of shorter fibrils. The resulting kinetic and morphological
measurements, therefore, indicate that TRO and SQ modulate
the assembly of Aβ42 in a very similar manner by stimulating
secondary nucleation.
We then quantified the effects of the aminosterol derivatives
on αS aggregation. In a similar manner as previously described
(Perni et al., 2017), the lipid-induced aggregation of 100 µM
monomeric αS with 100 µM DMPS vesicles was monitored
over time using ThT at a concentration of 50 µM (20 mM
phosphate buffer, pH 6.5, 0.01% NaN3) in the absence and
presence of increasing concentrations of aminosterols (1–10 µM)
(Figure 3). In agreement with previous findings for SQ (Perni
et al., 2017), we observe that the molecules inhibited the rate
of lipid-induced nucleation and reduced the quantity of ThT-
sensitive aggregates that formed during the aggregation process.
We note that these conditions are used for monitoring lipid-
induced nucleation in αS aggregation, whereas fibril elongation
or secondary nucleation can be studied specifically by changing
the solution conditions through the addition of fibril seeds or
acidification of the aggregation reaction, respectively (Buell et al.,
2014). The effects observed herein for aminosterols are, therefore,
likely related to the initiation steps in αS aggregation, rather
than secondary processes. As described previously, SQ displaces
monomeric αS from the vesicle surfaces, thereby blocking the first
steps in its aggregation process (Perni et al., 2017).
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FIGURE 3 | Aminosterols inhibit the lipid-induced nucleation of αS. Kinetic profiles of the aggregation of 100 µM αS with 100 µM
1,2-dimyristoyl-sn-glycero-3-phospho-L-serine (DMPS) vesicles in the absence (black) or presence of 1 (green), 2.5 (orange), 5 (red), and 10 (dark red) µM
concentrations of TRO (A), SQ (B), αSQ (C), and desSQ (D). Data represent mean ± s.e.m. of three technical replicates.
We finally compared the effects of these four aminosterols
for both aggregation reactions and found the results to be
highly similar, where Aβ42 was enhanced and αS inhibited to
comparable extents, as shown by comparing the aggregation
traces in the presence of either one molar equivalent of
each aminosterol in the presence of Aβ42 (Figure 4A) or
10 µM of each molecule for αS (Figure 4B), illustrating
that aminosterols enhance the monomer-dependent secondary
nucleation microscopic step in Aβ42 aggregation (Figure 4C)
and inhibit the lipid-induced primary nucleation process in αS
aggregation (Figure 4D).
Aminosterol Derivatives Modulate the
Size–Hydrophobicity Relationship of
Stabilized Oligomers
After resolving the kinetics associated with oligomer formation
for the aggregation reactions of αS and Aβ42 in the presence of
aminosterols, we next sought to characterize the effects of these
molecules on oligomeric aggregates of αS (Chen et al., 2015)
and Aβ40 stabilized by Zn2+ ions (Mannini et al., 2018). These
model species may represent the toxic aggregates observed in
pathology due to their formation protocol or stabilization by
a metal ion naturally present at the synaptic cleft, respectively.
In doing so, we sought to elucidate if all the aminosterols
studied here could modulate the size or hydrophobicity of
these stabilized oligomers, given that these properties have been
demonstrated to be key mediators of oligomer toxicity (Mannini
et al., 2014; Limbocker et al., 2020a). TRO was previously shown
to function at concentrations at and below molar equivalence
with respect to oligomers to prevent oligomer binding and
toxicity, and these concentrations did not significantly change
the structural properties of oligomers that play a central role
in their ability to induce dysfunction (Limbocker et al., 2020b).
Higher concentrations of TRO in excess of its physiological range
and rationally designed antibodies, however, have been shown
to increase the size and hydrophobicity of Zn2+-stabilized Aβ40
oligomers (Limbocker et al., 2020a). In the experiments with
antibodies, both the size and hydrophobicity were increased in
a similar fashion and with an approximately linear relationship,
which would be expected to cause an offsetting decrease and
increase in oligomer toxicity, respectively. Experimentally, Aβ40
oligomer toxicity did not change after incubation with the
designed antibodies (Limbocker et al., 2020a). In the experiments
with TRO, both the size and hydrophobicity were also increased
in a similar fashion and approximately linear relationship, but
toxicity was not tested in this case due to the inherent toxicity of
TRO to cells above a concentration of circa 6 µM, where these
physiochemical modifications were observed for the oligomers
(Limbocker et al., 2020a).
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FIGURE 4 | Aminosterols modify the aggregation processes of Aβ42 and αS. (A) Kinetic profiles of the aggregation of 2 µM Aβ42 in the absence (black) or presence
of an equimolar concentration of each aminosterol (represented with various colors). The bar plot shows the half-time of Aβ42 aggregation in the absence or
presence of the aminosterols. (B) Kinetic profiles of the aggregation of 100 µM αS in the absence (black) or presence of 10 µM of each aminosterol (represented
with various colors). Since trodusquemine has been characterized not to quench ThT or self-assemble into larger species under these conditions (Perni et al., 2018),
the decrease in ThT signal for the aminosterols studied is not likely related to ThT artifacts or assemblies of TRO, such as micelles. The bar plot shows the ThT signal
quantified after 30 h of αS aggregation in the absence or presence of the aminosterols. In panels (A–D), data represent mean ± s.e.m. of three technical replicates
and are the kinetic traces reproduced from Figures 2, 3. (C) Schematic illustration of the effect of aminosterols (AM) on Aβ42 aggregation, where they enhance
monomer-dependent secondary nucleation (k2). (D) Schematic illustration of the effect of aminosterols on αS aggregation, where they inhibit lipid-induced primary
nucleation.
In addition to studying the pathologically linked oligomers
of αS and Aβ40, we also investigated toxic oligomers of HypF-
N, an E. coli protein not associated with human pathology,
as a generic model of misfolded protein oligomers (Campioni
et al., 2010). After oligomer formation, solutions containing the
molecules were incubated for 1 h at 20◦C in the absence or
presence of increasing concentrations of the four aminosterols
(0–50 µM), after which time 15 µM 8-anilinonaphthalene-1-
sulfonate (ANS) was added to probe the hydrophobicity of
the oligomers. The same samples were also analyzed for their
turbidity absorbance using a plate reader. We observed that the
hydrophobicity (Figures 5A–C and Supplementary Figures 3–
5) and size (Figures 5D–F and Supplementary Figures 3–5)
of the oligomers were augmented in the presence of increasing
concentrations of all four aminosterols for oligomers of αS, Aβ40,
and HypF-N as measured using ANS binding and absorbance, in
agreement with our previous characterization of Aβ40 oligomers
and TRO (Limbocker et al., 2020a). In these assays and at molar
excess concentrations, the aminosterol derivatives exhibited
similar behaviors (Figure 5 and Supplementary Figures 3–
5). For all oligomer systems and as previously described for
high concentrations of TRO and specific rationally designed
antibodies (Limbocker et al., 2020a) with Zn2+-stabilized Aβ40
oligomers, a concomitant increase in size and hydrophobicity
was observed with increasing concentrations of aminosterols.
These effects would be expected not to change the toxicity
of the oligomers, as previously described in detail (Limbocker
et al., 2020a), as typically an increase in oligomer size is
protective against oligomer toxicity, while an increase in their
hydrophobicity is deleterious.
To further characterize the size of the aggregates in
the absence of ANS, we performed high-resolution, phase-
controlled AFM using a recently developed microfluidic spraying
platform (Ruggeri et al., 2018). This technology circumvents
mass-transport processes that can lead to artifacts resulting from
the drying process of an aqueous solution during conventional
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FIGURE 5 | Aminosterols modify the hydrophobicity and size of αS, Aβ40 stabilized by Zn2+, and HypF-N oligomers. (A–F) 8-Anilinonaphthalene-1-sulfonate (ANS)
binding measurements to probe the hydrophobicity of oligomers (5 µM in monomer equivalents) of αS (A), Aβ40 (B), and HypF-N (C) with corresponding size
changes monitored by turbidity absorbance (D–F) in the absence and presence of a 10-fold excess of SQ, TRO, αSQ, and desSQ (represented in different colors).
ANS alone is shown for reference in (A–C) (purple). Data represent mean ± s.e.m. of two technical replicates. Dose-dependent measurements for ANS fluorescence
and turbidity absorbance can be found in Supplementary Figures 3–5 ranging from 0 to 50 µM of each aminosterol. A 50 µM concentration of each aminosterol in
the absence of oligomers did not noticeably impact ANS fluorescence or turbidity absorbance relative to the effect observed for oligomers and the respective
concentrations of each molecule (Supplementary Figures 3–5). (G) The indicated oligomers in the absence and presence of a fivefold excess of SQ visualized
using high-resolution, phase-controlled AFM after sample preparation using a microfluidic device (Ruggeri et al., 2018).
AFM sample preparation processes, as the device sprays sub-
picoliter volumes that dry nearly instantaneously on the mica
substrate (Ruggeri et al., 2018). Given the similarity in the
bulk oligomer measurements (Figures 5A–F) and aggregation
experiments (Figures 2–4), we elected to further investigate only
SQ in detail. Oligomers were incubated as previously described
in the absence or presence of a fivefold excess concentration of
SQ and diluted in buffer by a factor of five prior to deposition
atop a mica substrate for AFM imaging. When quantified by
AFM, oligomers typically have a cross-sectional height of 2–6 nm
for HypF-N (Campioni et al., 2010), 1–5 nm for Zn2+-stabilized
Aβ40, and 3–16 nm for αS (Chen et al., 2015). The presence of
significantly larger aggregates was observed in the presence of SQ
for all three oligomer systems (Figure 5G), in direct agreement
with the turbidity data.
Squalamine Attenuates the Toxicity of
Oligomers by Displacing Them From Cell
Membranes
Following the above observations that SQ and its derivatives
exerted similar modifications to the kinetics of aggregation and
the physicochemical properties of oligomers in comparison with
TRO, previous observations that SQ displaces αS oligomers
from cell membranes (Perni et al., 2017), and considering
that cellular assays have significantly lower throughput than
the aforementioned biophysical and kinetic experiments, we
sought to determine if SQ also possessed the ability to displace
toxic oligomers of previously unexplored proteins from multiple
protein sources from cell membranes, thereby reducing the
deleterious effects of these aggregates. To begin, we first explored
the impact of SQ treatment for 24 h at 37◦C on SH-SY5Y
neuroblastoma cells using the MTT reduction assay, which
assesses the viability of cells (Perni et al., 2017). In our
previous study, we found that SQ did not significantly change
the viability of cells up to the maximum tested concentration
of 3 µM (Perni et al., 2017). In direct agreement with our
previous results, these new measurements indicate that SQ
treatment does not change the overall health of the cells at
concentrations equal to or below 3 µM, as seen by the MTT
reduction relative to untreated cells. However, we observed that
cell viability was decreased by 12 ± 4% upon the exposure
of cells to 10 µM SQ (Figure 6A), thus, highlighting the
physiological range of SQ in these cells and that concentration
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FIGURE 6 | Squalamine suppresses the toxicity associated with Aβ42 oligomeric species to neuroblastoma cells. (A) Aβ-derived diffusible ligands (ADDLs) of Aβ42
(denoted Aβ42 oligomers) were resuspended in cell culture medium at a concentration of 1 µM (in monomer equivalents) and incubated with or without increasing
concentrations (0.1, 0.33, 1, 3, and 10 µM) of SQ (red bars) for 1 h at 37◦C and then added to the cell culture medium of SH-SY5Y cells for 24 h. The cells were
also treated with the same concentrations of SQ pre-incubated in the absence of oligomers for 1 h at 37◦C (white bars). (B) Representative confocal scanning
microscopy images of the apical planes of cells treated for 15 min with Aβ42 oligomers (1 µM in monomer equivalents) in the absence or presence of 10 µM SQ.
Red and green fluorescence indicates the cell membranes and the Aβ42 oligomers, respectively. Scale bar = 10 µm. (C) The histogram shows the percentage of
colocalization on regions of interest (12–22 cells). In all panels, data represent mean ± s.e.m. of three independent experiments, the symbols ** and *** indicate
p < 0.01 and 0.001, respectively, relative to untreated cells, and the symbol ◦◦◦ indicates p < 0.001 relative to cells treated with oligomers.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) data were analyzed by one-way ANOVA followed by Bonferroni’s post comparison test. Cell
binding data were analyzed using an unpaired, two-tailed Student’s t-test.
of SQ at and above 10 µM can cause small, but relevant
reductions in cell health.
Next, Aβ42 oligomers (ADDLs) were prepared and incubated
(1 µM in monomer equivalents) with increasing concentrations
of SQ (0.1 to 10 µM) for 1 h at 37◦C in a cell culture medium
and then incubated with SH-SY5Y neuroblastoma cells for 24 h
at 37◦C. Viability was measured using the aforementioned MTT
assay, and a dose-dependent decrease in oligomer toxicity was
observed with increasing concentrations of SQ (Figure 6A). The
fact that 10 µM SQ alone decreased cell health by 12 ± 4%,
whereas cells treated with both 10 µM SQ and oligomers had
a viability level of 100 ± 3% relative to untreated cells is likely
related to the binding of SQ to the oligomers, which would reduce
the effective concentration of SQ delivered to the cells.
In light of the similarities between SQ and TRO in
ameliorating the toxicity caused by protein misfolding oligomers
to human neuroblastoma cells, we next explored the quantity of
aggregates which were able to interact with cell membranes in the
absence and presence of the SQ, as previously described (Perni
et al., 2017). Confocal microscopy experiments were employed
to measure oligomer binding to apical planes of cell membranes
in the presence of 10 µM SQ, for which a decrease in aggregate
binding by 69± 4% was observed (Figures 6B,C). We refer to this
effect as a displacement as SQ was originally shown to displace
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monomeric and oligomer forms of αS from the membranes of
vesicles and cells, respectively (Perni et al., 2017). Moreover, the
similar TRO compound was shown to bind to the membrane
with high affinity (<500 nM) and make it refractory to the
binding of the oligomers (Errico et al., 2020). It is, therefore,
likely that aminosterols function by displacing oligomers and
by preventing their association with cell membranes prior to
oligomer binding. Collectively, the MTT and binding results are
highly similar as those obtained for TRO, with the exception
that 10 times more molecule was necessary in the case of
SQ to observe comparable effects to TRO from our previous
publication for cell viability experiments and measurements on
the extent of oligomer binding to cell membranes (Limbocker
et al., 2019). These results are therefore similar mechanistically
to those obtained for TRO in the presence of multiple types of
oligomers (Limbocker et al., 2020b).
We then sought to determine if the observation that greater
concentrations of SQ were necessary to observe the same
effect as a lesser amount of TRO could be validated by
studying the toxicity and membrane interaction affinity of HypF-
N and Zn2+-stabilized Aβ40 oligomers in the absence and
presence of SQ. In a highly similar manner as described for
Aβ42 oligomers, MTT measurements were carried out with
a pre-incubation step of 1 h at 37◦C for HypF-N oligomers
(6 µM in monomer equivalents) in the presence of increasing
concentrations of SQ (0.1-, 0.33-, 1-, and 3-fold excesses).
Similar to as described above, we observed that cell viability
was decreased by 13 ± 5% upon the exposure of cells to
18 µM SQ in the absence of oligomers (Figure 7A), further
confirming that concentrations of SQ at and above 10 µM
can cause small decreases in cell health. We next observed
that this aminosterol induced a dose-dependent decrease in
HypF-N oligomer toxicity. We also measured the toxicity of
the Aβ40 oligomers (5 µM in monomer equivalents) in the
presence of a threefold excess of SQ, for which a near-complete
attenuation of toxicity was revealed. Indeed, the toxicities for
both types of oligomers in the presence of a threefold excess
of SQ was not significantly different than the toxicity resulting
FIGURE 7 | Squalamine reduces the membrane binding affinity and related toxicity of Aβ40 stabilized by Zn2+ and HypF-N oligomers to cultured human
neuroblastoma cells. (A) HypF-N oligomers (6 µM in monomer equivalents) were resuspended in cell culture medium in the absence and presence of 0.1, 0.33, 1,
and 3 molar equivalents of SQ (blue), incubated (1 h, 37◦C), and subsequently added to the cell culture medium of SH-SY5Y cells for 24 h. Cells were treated under
the same conditions with 18 µM SQ in the absence of oligomers (white bar). Similarly, Zn2+-stabilized Aβ40 oligomers (5 µM in monomer equivalents) were
resuspended in cell culture medium in the absence and presence of a 1:3 ratio of Aβ40-to-SQ (red). (B) Representative confocal scanning microscopy images of the
apical sections of SH-SY5Y cells treated for 15 min with HypF-N oligomers (6 µM in monomer equivalents, left panels) and Zn2+-stabilized Aβ40 oligomers (5 µM in
monomer equivalents, right panels) in the absence and presence of a 1:3 ratio of oligomers-to-SQ. Red and green fluorescence indicates the cell membranes and
the oligomers, respectively. Scale bar = 10 µm. (C) Histograms show the percentage of colocalization between membranes and oligomers in the regions of interest
(12–22 cells in total). In all panels, data represent mean ± s.e.m. of three independent experiments, the symbols * and *** indicate p < 0.05 and 0.001, respectively,
relative to untreated cells, and the symbols ◦, ◦◦, and ◦◦◦ indicate p < 0.05, 0.01, and 0.001, respectively, relative to cells treated with oligomers. MTT data were
analyzed by one-way ANOVA followed by Bonferroni’s post comparison test. Cell binding data were analyzed using an unpaired, two-tailed Student’s t-test.
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from the molecule alone (Figure 7A), suggesting that the
oligomers are largely inert in terms of their ability to induce
cellular dysfunction under these conditions. Oligomer toxicity
has been previously observed to plateau at a concentration of
approximately 6 µM for HypF-N oligomers and 5 µM for Zn2+-
stabilized Aβ40 oligomers (Limbocker et al., 2020b), which is
broadly consistent with the oligomer toxicities observed here.
Given that greater concentrations of oligomers for HypF-N and
Zn2+-stabilized Aβ40 were required in our measurements to
observe a comparable decrease in cell viability with respect to
only 1 µM Aβ42 oligomers, it was not pragmatic to explore ratios
greater than a threefold excess of SQ-to-oligomers for HypF-N
and Aβ40 oligomers due to the intrinsic toxicity of SQ above
10 µM (Figures 6A, 7A).
Finally, HypF-N and Aβ40 oligomers (6 and 5 µM, in
monomer equivalents, respectively) were incubated with cells for
15 min as previous described in the absence and presence of a
threefold excess of SQ. Confocal microscopy was employed as
previously described (Perni et al., 2017) to measure the extent
of the interaction of the oligomers with the cellular membrane.
Extensive oligomer binding was observed in the absence of the
molecule, but in its presence, the bound fraction was dramatically
reduced (Figure 7B), as only 33 ± 2% of Aβ40 oligomers and
38 ± 3% of HypF-N oligomers were localized to neuroblastoma
cell membranes in the presence of a threefold excess of SQ relative
to cells treated with oligomers alone (Figure 7C). We, therefore,
conclude that SQ and TRO are equivalent in their mechanism
of function with respect to the suppression of oligomer toxicity
via their displacement from cell membranes, with a major
difference arising from the observation that three times greater
concentrations of SQ for these protein systems were needed
to observe comparable effects in comparison with TRO from
Limbocker et al. (2020b). Therefore, SQ appears to be equally
effective in these cellular assays at displacing oligomers and
preventing their toxicity relative to TRO; however, a three- to 10-
fold greater concentration of SQ was needed to observe the same
effects for TRO, dependent upon the proteinaceous composition
of oligomeric species under investigation (Figures 6–8).
DISCUSSION
The results that we have presented extend to SQ the previous
conclusion obtained with TRO (Perni et al., 2017, 2018;
Limbocker et al., 2019, 2020b) that aminosterols can outcompete
oligomers and induce the displacement of these cytotoxic
aggregates of multiple protein sources from cell membranes,
thereby suppressing the damage caused by protein aggregation.
At low TRO concentrations, TRO seems to bind to the
membrane, not oligomers (Limbocker et al., 2020b). At high
TRO concentrations, there is an excess of TRO, and binding
is also observed in the oligomers in addition to the membrane
(Limbocker et al., 2020a). At small TRO concentrations, binding
to the membrane prevails. In contrast, the effects of these
compounds on the overall aggregation reactions were found to
be different on the two proteins, Aβ42 and αS, that we studied.
Similar to our previous finding on TRO (Limbocker et al.,
2019), SQ targeted and enhanced the rate of Aβ42 aggregation
by potentiating mostly the secondary nucleation microscopic
step to produce shorter and wider fibrils, which likely also
FIGURE 8 | Schematic representation of the effect of aminosterols on isolated or stabilized oligomers of αS, Aβ40 stabilized by Zn2+, and HypF-N. After oligomer
isolation or stabilization, the addition of aminosterols (AM) to the reaction mixture can induce the non-physiological clustering of the aggregates at high
concentrations (shown as gray species), and the physiologically relevant displacement of oligomers from cell membranes at low concentrations (toxic oligomers are
shown as red species). For the latter scenario, trodusquemine exhibited comparable effects with squalamine at 3–10× lower concentrations of the molecule,
signaling its enhanced efficacy at displacing protein misfolded oligomers from cell membranes.
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hastens the conversion of more harmful oligomers to relatively
inert fibrillar aggregates. αS was targeted differently by these
aminosterols, as they inhibited its aggregation by suppressing
lipid-induced nucleation, as found here for SQ and its derivatives
and previously with TRO (Perni et al., 2018). In a previous report,
it was also found that the fibril amplification of αS was also
inhibited by TRO (Perni et al., 2018), although this microscopic
step was not studied with SQ. Both this inhibition on αS
aggregation and acceleration on Aβ42 fibril formation can reduce
oligomer toxicity by decreasing the number of toxic species
produced over time. In addition to modulating the aggregation
kinetics in modes that may work to suppress the populations of
toxic species, we further observed that the aminosterols directly
displace such toxic species from cell membranes. While both
aminosterols were efficacious in reducing toxicity, TRO appears
to have a higher efficacy than SQ given its ability to achieve
comparable protective levels at 3–10 times less molecules, which
may result from the differing polyamine structures fused to
the sterol rings.
For stabilized oligomers, we have shown previously that the
predominant means by which TRO protects cells from stabilized
oligomers of αS, Aβ40, and HypF-N is through their displacement
from cell membranes, rather than a change in oligomer structure
at physiologically relevant concentrations (Limbocker et al.,
2020b). This results from the ability of TRO to bind with high
affinity (<500 nM) to the hydrophilic portion of the phospholipid
bilayer. In particular, this small molecule was found to localize
within the external hydrophilic layer down to the interface
between the hydrophilic and hydrophobic layers with a well-
defined angle of ca. 55◦ for the major axis of the molecule
with respect to the normal to the bilayer plane and a superficial
positioning of the positively charged spermine moiety (Errico
et al., 2020). This causes a decrease in its negative charge, its
reinforcement against oligomer penetration, and a redistribution
of its cholesterol and ganglioside GM1 molecules, all known
to reinforce the membrane against the deleterious action of
misfolded protein oligomers (Errico et al., 2020). The increase
in oligomer size observed herein upon SQ addition is expected
to reduce oligomer toxicity toward cells, while the increase
in oligomer hydrophobicity would be expected to increase
the ability of these species to interact with cell membranes
and induce dysfunction (Mannini et al., 2014; Cappelli et al.,
2016; Limbocker et al., 2020a). The increase in both size and
hydrophobicity would, therefore, be expected to offset each other
in terms of their effects on oligomer cytotoxicity, as was shown
recently with very similar size–hydrophobicity relationships
using increasing concentrations of rationally designed antibodies
and Aβ40 oligomers (Limbocker et al., 2020a). However, this
effect is not likely to be physiological given the high aminosterol
concentration regimes used to observe these physicochemical
changes in vitro. These results obtained here with SQ, therefore,
agree with our previous conclusion that the dominant mode by
which TRO prevents oligomer toxicity is by their displacement
from cell membranes.
As seminal agents in numerous protein misfolding diseases,
we focused in this report on the misfolded oligomers formed
by these proteins rather than on other conformers. We note,
however, that aminosterols have been shown to bind to
amyloid fibrils (Perni et al., 2017, 2018), resulting in the
enhancement of monomer-dependent secondary nucleation for
Aβ42 (Limbocker et al., 2019) and the inhibition of fibril
amplification for αS (Perni et al., 2018). Squalamine can bind
monomeric αS at high concentrations, causing small chemical
shifts in the C-terminal region of the protein (Perni et al.,
2017); however, trodusquemine was found not to impact the
normal association of monomeric αS with DMPS vesicles at
physiological concentrations (Perni et al., 2018). The detailed
molecular mechanism by which aminosterols bind these different
proteins and conformers is an important topic for future work
that has key implications for the rate of oligomer formation
during the aforementioned processes and could explain why
Aβ42 aggregation is enhanced and αS nucleation reduced
by aminosterols.
Relative to the other aminosterols, we observed that desSQ
modulates the aggregation of Aβ42 and αS to a lesser extent
(Figure 4). Similarly, desSQ demonstrated a reduced ability
to modify the size of stabilized oligomers (Figure 5 and
Supplementary Figures 3–5). Collectively, these data suggest
that the anionic group in this position on the sterol side chain
(Figure 1) may be important to its activity. As the behavior of
αSQ and SQ were highly similar across all our measurements,
these data further suggest that the chirality of the polyamine with
respect to the sterol may not be essential to its activity.
The difference in effectiveness between TRO and SQ points
toward slight differences in structure that may highlight the
framework for a rational approach toward identifying and
developing countermeasures for differing neurodegenerative
diseases. TRO and SQ have spermine and spermidine polyamine
side chains, respectively, and they are both small molecules
with a hydrophobic sterol domain that can integrate into cell
membranes. Moreover, the aminosterol derivatives differ in their
carbon skeletons and the distribution of their functional groups.
The difference of one positive charge between SQ and TRO in its
side chain appeared to have a significant impact on the respective
efficacies of these aminosterols, with the more charged TRO
having an apparently 3–10 times greater protective power relative
to an equivalent concentration of SQ. This argument is supported
by the observation that TRO decreases the negative charge of the
membrane, as determined with zeta-potential measurements, and
neutralizes in part the negative moieties of the ganglioside GM1
(Errico et al., 2020), known to mediate oligomer–membrane
interaction and oligomer toxicity (Evangelisti et al., 2016). A less
positively charged SQ very likely can only be less effective in
causing this neutralization. Additionally, TRO has been reported
to be able to cross the blood–brain barrier, whereas SQ has not
(Lantz et al., 2010), which could potentially impact the utility
of these molecules in clinical trials against neurodegenerative
disease. These results also point to the potential of other members
of the aminosterol family that could be synthesized in the
future, which may be differentially efficacious based on similar
alterations in structure and electrostatic interactions.
Collectively, these results highlight that small alterations in the
structure of squalamine derivatives can alter their effectiveness
against the toxic oligomers causing protein misfolding diseases.
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Moreover, our research highlights the differences between the
aggregation processes in AD and PD, resulting in unique
responses to the same aminosterols. Despite the differences in
the aggregation reactions of these proteins at a fundamental
level, both SQ and TRO appear to be effective in decreasing
the concentration of cytotoxic protein aggregates of both
proteins. In addition, they were effective in counteracting
the cytotoxicity of both protein systems, demonstrating that
membrane displacement is likely to be an effective strategy for
combatting multiple protein misfolding diseases. These results,
along with the observed differences in molecule effectiveness,
point toward a rational framework for the identification
and development of small molecule therapeutics that address
oligomer cytotoxicity through membrane displacement.
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